Precipice Holdings Limited Acquires Common Shares of Nova Leap Health Corp.
Precipice Holdings Limited Acquires Common Shares of Nova Leap Health Corp.
HALIFAX, Nova Scotia, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Precipice Holdings Limited ("Precipice") announces that it has acquired 118,200 common shares ("Common Shares") of Nova Leap Health Corp. (TSXV: NLH) ("Nova Leap"), with its head office at 3006-7071 Bayers Road, Halifax, Nova Scotia, B3L 2C2, representing approximately 0.14% of the Common Shares issued and outstanding. Precipice is a holding company incorporated under the laws of the Province of Nova Scotia owned and controlled by Chris Dobbin, President & CEO of Nova Leap.
新斯科舍省哈利法克斯,2024年1月2日(GLOBE NEWSWIRE)——Precipice Holdings Limited(“Precipice”)宣佈已收購Nova Leap Health Corp.(多倫多證券交易所股票代碼:NLH)(“Nova Leap”)的118,200股普通股(“普通股”),其總部位於新斯科舍省哈利法克斯拜耳路3006-7071號,代表B3L 2C2 約佔已發行和流通普通股的0.14%。Precipice是一家根據新斯科舍省法律註冊成立的控股公司,由Nova Leap總裁兼首席執行官克里斯·多賓擁有和控制。
On December 29, 2023, Precipice acquired 118,200 Common Shares in the open market on the TSX Venture Exchange with purchase prices between $0.23 and $0.30 per share, for total consideration of $29,358 (the "Transaction").
2023年12月29日,Precipice在多倫多證券交易所風險交易所的公開市場上收購了118,200股普通股,收購價格在每股0.23美元至0.30美元之間,總對價爲29,358美元(“交易”)。
Before the Transaction, Precipice and its joint actors collectively controlled 8,519,033 Common Shares representing 9.88% of the outstanding Common Shares. Following completion of the Transaction, Precipice and its joint actors own and control 8,637,233 Common Shares or 10.02% of the outstanding Common Shares.
交易前,Precipice及其聯合行爲人共同控制了8,519,033股普通股,佔已發行普通股的9.88%。交易完成後,Precice及其合夥人擁有並控制8,637,233股普通股,佔已發行普通股的10.02%。
The purpose of the Transaction was for investment purposes. Precipice and its joint actors may, from time to time, increase or decrease their holdings of securities of Nova Leap, depending on market and other conditions.
本次交易的目的是爲了投資目的。根據市場和其他條件,Precipice及其聯合參與者可能會不時增加或減少其持有的Nova Leap證券。
Further details on the information above concerning Precipice may be obtained from the Early Warning Report filed on SEDAR or by contacting Chris Dobbin, President & CEO of Nova Leap Health Corp. at 902-401-9480.
有關上述有關Precipice的信息的更多詳細信息,可從SEDAR提交的預警報告中獲得,也可以致電902-401-9480與Nova Leap Health Corp.總裁兼首席執行官克里斯·多賓聯繫。
CONTACT: cdobbin@novaleaphealth.com
聯繫人:cdobbin@novaleaphealth.com
譯文內容由第三人軟體翻譯。